Literature DB >> 18762813

Association of FGFR4 genetic polymorphisms with prostate cancer risk and prognosis.

L M FitzGerald1, E Karlins, D M Karyadi, E M Kwon, J S Koopmeiners, J L Stanford, E A Ostrander.   

Abstract

The fibroblast growth factor receptor 4 (FGFR4) is thought to be involved in many critical cellular processes and has been associated with prostate cancer risk. Four single nucleotide polymorphisms (SNPs) within or near FGFR4 were analyzed in a population-based study of 1458 prostate cancer patients and 1352 age-matched controls. We found no evidence to suggest that any of the FGFR4 SNP genotypes were associated with prostate cancer risk or with disease aggressiveness, Gleason score or stage. A weak association was seen between rs351855 and prostate cancer-specific mortality. Subset analysis of cases that had undergone radical prostatectomy revealed an association between rs351855 and prostate cancer risk. Although our results confirm an association between FGFR4 and prostate cancer risk in radical prostatectomy cases, they suggest that the role of FGFR4 in disease risk and outcomes at a population-based level appears to be minor.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18762813      PMCID: PMC2790323          DOI: 10.1038/pcan.2008.46

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  29 in total

1.  Increased expression of the metastasis-associated gene Ehm2 in prostate cancer.

Authors:  Jianghua Wang; Yi Cai; Rebecca Penland; Sanjay Chauhan; Roger L Miesfeld; Michael Ittmann
Journal:  Prostate       Date:  2006-11-01       Impact factor: 4.104

2.  High frequency of fibroblast growth factor (FGF) 8 expression in clinical prostate cancers and breast tissues, immunohistochemically demonstrated by a newly established neutralizing monoclonal antibody against FGF 8.

Authors:  A Tanaka; A Furuya; M Yamasaki; N Hanai; K Kuriki; T Kamiakito; Y Kobayashi; H Yoshida; M Koike; M Fukayama
Journal:  Cancer Res       Date:  1998-05-15       Impact factor: 12.701

3.  FGFR4 Gly388Arg polymorphism and prognosis of breast and colorectal cancer.

Authors:  Monica Spinola; Vera Piera Leoni; Jun-Ichi Tanuma; Angela Pettinicchio; Milo Frattini; Stefano Signoroni; Roberto Agresti; Riccardo Giovanazzi; Silvana Pilotti; Lucio Bertario; Fernando Ravagnani; Tommaso A Dragani
Journal:  Oncol Rep       Date:  2005-08       Impact factor: 3.906

4.  FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer.

Authors:  Christoph Thussbas; Jorg Nahrig; Sylvia Streit; Johannes Bange; Monika Kriner; Ronald Kates; Kurt Ulm; Marion Kiechle; Heinz Hoefler; Axel Ullrich; Nadia Harbeck
Journal:  J Clin Oncol       Date:  2006-07-05       Impact factor: 44.544

Review 5.  Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies.

Authors:  S A Rabbani; R H Xing
Journal:  Int J Oncol       Date:  1998-04       Impact factor: 5.650

6.  FGFR4 GLY388 isotype suppresses motility of MDA-MB-231 breast cancer cells by EDG-2 gene repression.

Authors:  Christiane Regina Stadler; Pjotr Knyazev; Johannes Bange; Axel Ullrich
Journal:  Cell Signal       Date:  2005-08-18       Impact factor: 4.315

7.  Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients.

Authors:  Monica Spinola; Vera Leoni; Carmen Pignatiello; Barbara Conti; Fernando Ravagnani; Ugo Pastorino; Tommaso A Dragani
Journal:  J Clin Oncol       Date:  2005-08-01       Impact factor: 44.544

8.  Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer.

Authors:  B Gowardhan; D A Douglas; M E Mathers; A B McKie; S R C McCracken; C N Robson; H Y Leung
Journal:  Br J Cancer       Date:  2005-01-31       Impact factor: 7.640

9.  Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer.

Authors:  K Sahadevan; S Darby; H Y Leung; M E Mathers; C N Robson; V J Gnanapragasam
Journal:  J Pathol       Date:  2007-09       Impact factor: 7.996

10.  Further observations on the relationship between the FGFR4 Gly388Arg polymorphism and lung cancer prognosis.

Authors:  A Matakidou; R El Galta; M F Rudd; E L Webb; H Bridle; T Eisen; R S Houlston
Journal:  Br J Cancer       Date:  2007-05-22       Impact factor: 7.640

View more
  14 in total

1.  Fibroblast growth factor receptor 4 Gly388Arg polymorphism in Chinese gastric cancer patients.

Authors:  Yan-Ying Shen; Ya-Chao Lu; Dan-Ping Shen; Yuan-Jie Liu; Xin-Ying Su; Guan-Shan Zhu; Xiao-Lu Yin; Xing-Zhi Ni
Journal:  World J Gastroenterol       Date:  2013-07-28       Impact factor: 5.742

2.  Polymorphisms of FGFR1 in HBV-related hepatocellular carcinoma.

Authors:  Haiyang Xie; Chunyang Xing; Bajin Wei; Xiao Xu; Liming Wu; Jian Wu; Leiming Chen; Guoqiang Cao; Hai Chen; Xueqin Meng; Shengyong Yin; Lin Zhou; Shusen Zheng
Journal:  Tumour Biol       Date:  2015-06-12

Review 3.  Gene variants in the angiogenesis pathway and prostate cancer.

Authors:  Ernest K Amankwah; Thomas A Sellers; Jong Y Park
Journal:  Carcinogenesis       Date:  2012-04-20       Impact factor: 4.944

Review 4.  Factors underlying sensitivity of cancers to small-molecule kinase inhibitors.

Authors:  Pasi A Jänne; Nathanael Gray; Jeff Settleman
Journal:  Nat Rev Drug Discov       Date:  2009-07-24       Impact factor: 84.694

Review 5.  Is fibroblast growth factor receptor 4 a suitable target of cancer therapy?

Authors:  Christine Heinzle; Zeynep Erdem; Jakob Paur; Bettina Grasl-Kraupp; Klaus Holzmann; Michael Grusch; Walter Berger; Brigitte Marian
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

6.  FGFR4 Gly388Arg polymorphism contributes to prostate cancer development and progression: a meta-analysis of 2618 cases and 2305 controls.

Authors:  Bin Xu; Na Tong; Shu Q Chen; Li X Hua; Zeng J Wang; Zheng D Zhang; Ming Chen
Journal:  BMC Cancer       Date:  2011-02-24       Impact factor: 4.430

Review 7.  Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers.

Authors:  Kai Hung Tiong; Li Yen Mah; Chee-Onn Leong
Journal:  Apoptosis       Date:  2013-12       Impact factor: 4.677

8.  Fibroblast growth factor receptor 4 polymorphism is associated with liver cirrhosis in hepatocarcinoma.

Authors:  Ming-Jen Sheu; Ming-Ju Hsieh; Whei-Ling Chiang; Shun-Fa Yang; Hsiang-Lin Lee; Liang-Ming Lee; Chao-Bin Yeh
Journal:  PLoS One       Date:  2015-04-10       Impact factor: 3.240

9.  Impact of FGFR4 Gene Polymorphism on the Progression of Colorectal Cancer.

Authors:  Bei-Hao Shiu; Ming-Hong Hsieh; Wen-Chien Ting; Ming-Chih Chou; Lun-Ching Chang; Chi-Chou Huang; Shih-Chi Su; Shun-Fa Yang
Journal:  Diagnostics (Basel)       Date:  2021-05-28

10.  FGFR4 role in epithelial-mesenchymal transition and its therapeutic value in colorectal cancer.

Authors:  Alberto Peláez-García; Rodrigo Barderas; Sofía Torres; Pablo Hernández-Varas; Joaquín Teixidó; Félix Bonilla; Antonio Garcia de Herreros; J Ignacio Casal
Journal:  PLoS One       Date:  2013-05-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.